



Understanding protein–drug interactions using ion mobility–mass spectrometry

Claire E Evers^{1,2}, Matthias Vonderach^{1,2}, Samantha Ferries^{1,2},
Kiani Jeacock² and Patrick A Evers²



Ion mobility–mass spectrometry (IM–MS) is an important addition to the analytical toolbox for the structural evaluation of proteins, and is enhancing many areas of biophysical analysis. Disease-associated proteins, including enzymes such as protein kinases, transcription factors exemplified by p53, and intrinsically disordered proteins, including those prone to aggregation, are all amenable to structural analysis by IM–MS. In this review we discuss how this powerful technique can be used to understand protein conformational dynamics and aggregation pathways, and in particular, the effect that small molecules, including clinically-relevant drugs, play in these processes. We also present examples of how IM–MS can be used as a relatively rapid screening strategy to evaluate the mechanisms and conformation-driven aspects of protein:ligand interactions.

Addresses

¹ Centre for Proteome Research, Institute of Integrative Biology, University of Liverpool, Liverpool L69 7ZB, United Kingdom

² Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool L69 7ZB, United Kingdom

Corresponding author: Evers, Claire E (CEvers@liverpool.ac.uk)

Current Opinion in Chemical Biology 2018, 42:167–176

This review comes from a themed issue on Omics

Edited by Erin Baker and Perdita Barran

<https://doi.org/10.1016/j.cbpa.2017.12.013>

1367-5931/© 2017 Published by Elsevier Ltd.

Introduction

An important consideration during drug development is the structural and mechanistic evaluation of the protein target, ideally combined with a multi-level understanding of how conformation and biological function are modulated by ligand binding. Ion mobility–mass spectrometry (IM–MS), which separates ions in the gas-phase based on their size (mass), shape and charge [1^{*},2–4,5^{*},6,7] has emerged as an important addition to more traditional structural biology techniques such as NMR, X-ray crystallography and Cryo-electron microscopy [8] and can be readily exploited to help understand conformational

dynamics of proteins and non-covalent protein complexes [9–11]. Although IM–MS is unable to reveal resolution at the atomic level, the ability to analyse heterogeneous complexes and protein–ligand interactions in their native conformations [11–18,19^{*}] offers a competitive advantage over other structural approaches, which either ‘fix’ the conformation, for example, during crystal formation, or are unable to handle mixtures. Indeed, the fact that analyte mass to charge (m/z) ratio is evaluated independently of ion mobility information means that IM–MS can be used to analyse heterogeneous populations; it also provides a means of analysing protein complexes that occupy multiple conformations, whilst providing important information on the stoichiometry of non-covalent complexes. Moreover, application of IM–MS for structural interrogation is typically much faster than other approaches, and only requires picomole amounts of material for analysis. IM–MS can thus be exploited as a stand-alone tool for protein structural interrogation, with or without *in silico* molecular modelling, or to complement high-resolution information acquired by other means [20]. For example, crystallographic evaluation of proteins (with or without bound ligands), particular those with disordered regions, often results in incomplete atomic structures [21]. Combining partial structural datasets with experimentally derived CCS information can therefore be used to constrain topological models through computational approaches. Coarse-grained and homology modelling has proven useful in this regard, being applied to structural modelling of numerous multimeric protein complexes with distinct topologies [22–25].

Although originally the subject of some debate, a significant body of evidence now demonstrates that in the majority of cases, the native solution-phase structure of a protein/protein:ligand complex can be retained in the gas phase [26,27] when ‘native’ ESI conditions are employed and analytical parameters are carefully controlled. Once in the gas-phase, the resulting ions can be separated based on two physical properties: their differential mobility through an inert gas in a weak electric field [28], and by employing standard m/z -based separation using mass spectrometry (MS). The primary purpose of this review is to describe how IM–MS has been applied to help understand different protein–drug interactions, rather than to provide a background to the different forms of this technique. Several comprehensive reviews detailing the fundamentals of IM–MS are available [1^{*},2,6,29]. Of most relevance to this article are drift tube IMS

(DTIMS) [3,30], trapped ion mobility IMS (TIMS) [31] and travelling wave IMS (TWIMS) [32], all of which are available on commercial instruments and can therefore be readily employed experimentally. These are discussed briefly below.

DTIMS employs a weak homogeneous electric field to direct ions through a drift cell, where collisions between ions and an inert buffer gas (typically helium or nitrogen) delay passage through the cell, allowing the rotationally averaged collisional cross section (CCS) of different ions to be measured directly. Unlike DTIMS, which directly assesses the drift time of ions in a ‘stationary’ gas, in TIMS, ions are trapped in the presence of a counter-flow of gas, with ions ‘eluting’ selectively according to their relative mobility through the gas. TWIMS is comparable to DTIMS, but uses a stacked ring ion guide (SRIG) through which ions are propelled by means of a travelling wave DC voltage superimposed onto a radially-confining RF voltage. Ions of high mobility will spend less time in the travelling wave ion guide (TWIG) than ions of low mobility as they will be more easily transported through the gas-filled mobility cell. Calibration of the time taken for ions of known CCS to travel through the TWIG can then be used to compute CCS values of unknown analytes of similar chemical structure under the same buffer and voltage conditions [33–36]. CCS reports median protein conformation, while concurrent measurement of the CCS distributions (CCSD) can be used to help evaluate conformational flexibility. Moreover, when experimental CCS information is compared with theoretical calculations for a given geometry, possible candidate structures can be proposed, ruled out or validated. Field asymmetric IMS (FAIMS), also called differential IMS, is an alternative method for separating gaseous ions at atmospheric pressure [37,38]. However, due to the non-linear effect of the applied electric field on ion mobility and its deleterious effect on native protein conformation, FAIMS cannot be used to determine CCS, but is instead used to separate mixtures. However, as with all IM–MS instrumentation, FAIMS can be exploited to determine the dissociation constant (K_D) of protein:ligand complexes, although this type of IMS is optimal for stronger non-covalent complexes. IM–MS derived K_D values are thought to be comparable with values obtained using more traditional solution approaches, such as fluorimetry, calorimetry, thermophoresis and Surface Plasmon Resonance (SPR).

Depending on the type of IM–MS employed, structural information pertaining to protein:ligand complexes can thus be obtained, including definition of K_D for reversible binding, and providing insight into whether ligands stabilise (or destabilize) protein conformations (see Figure 1). K_D values are determined using the titration method followed by a nonlinear curve fit using Eq. (1) [39]. $I(PL)$ and $I(P)$ define the peak area of the protein:

ligand complex and the unbound protein respectively; $[P]_0$ and $[L]_0$ are the original protein and ligand concentrations:

$$\frac{I(P*L)}{I(P)} = \frac{1}{2} \left(-1 - \frac{[P]_0}{K_D} + \frac{[L]_0}{K_D} + \sqrt{4 \frac{[L]_0}{K_D} + \left(\frac{[L]_0}{K_D} - \frac{[P]_0}{K_D} - 1 \right)^2} \right) \quad (1)$$

The effect of ligand binding on protein conformational stability can also be investigated using collision-induced unfolding (CIU) [40*,41,42]. Here, the intact protein or protein:ligand complex (or the remaining unbound protein) is subjected to a gradual increase in collisional activation below that required for protein or complex dissociation, thereby inducing protein unfolding. The (partially) unfolded protein states at different activation energies are then analysed by IM–MS, with the resultant ‘CIU fingerprint’ being used to define the partially unfolded transition states as a function of the applied energy (see Figure 1). Software packages, for example, CIUSuite, can assist with data interpretation [43] and, in the case of ORIGAMI, also automate acquisition of CIU fingerprints [44*].


As exemplars of the utility of IM–MS for structural characterisation of protein–ligand interactions, we will focus on three major classes of protein for which IM–MS has revealed important information: amyloid, intrinsically disordered proteins (IDPs) and protein kinases.

Amyloid

Protein aggregation and the formation of amyloid fibrils is thought to be a causative factor in over 50 human diseases including Alzheimer’s disease [45], Parkinson’s disease [46], type II diabetes [47], cardiovascular disease, and some forms of cancer [48]. IM–MS has been used to provide important insights into the self-assembly mechanisms of several distinct amyloidogenic proteins, including β 2-microglobulin, A β 40/A β 42 and α -synuclein [49*,50], helping to understand the assembly and architecture of fibrils and associated intermediates, and the effect of small molecules on these dynamic processes (Figure 2) [51**,52–55]. Recent work by Pagel and colleagues used a combination of infrared spectroscopy with IM–MS to directly analyse the secondary structure of individual amyloid intermediates, elegantly demonstrating that small fibril-forming 6-mer peptides yield oligomers comprising an extensive β -sheet architecture [56].

By contrast to other structural techniques, IM–MS can be used to characterise the multiple individual soluble aggregate forms present during the transition from monomers to insoluble fibrils, as opposed to an ‘average’ of properties forming an oligomer ensemble (Figure 2). One of the

Figure 1



Native IM–MS can yield information regarding the effect of ligand binding on protein conformation and stability. Ion mobility is used to resolve possible conformational changes. Acquiring arrival time distributions (ATDs) at different collision energies results in a CIU fingerprint and allows information to be obtained about ligand binding strength as well as conformational stability of the bound or unbound protein. Acquisition of mass spectra at different small molecule or ligand concentrations can be used to determine the strength of interaction by calculation of a dissociation constant K_D .

first studies demonstrating the applicability of IM–MS to amyloidosis was an analysis of early aggregation states of A β 42, a putative neurotoxic species in Alzheimer's disease [57]. The results of this investigation were in agreement with labour-intensive photochemical cross-linking experiments, and further supported by molecular modelling. A follow-on study revealed that the mechanism of A β 42 aggregation is different to that of A β 40, and demonstrated that the A β 42 dodecamer is likely to be the primary toxic species in Alzheimer's disease [51^{••}].

Crucial for the development of therapeutic strategies for amyloid-triggered disease is understanding the aggregation process in the presence of peptide or small molecule-based ligands (Figure 2) [58–62,63[•],64,65]. A classic example is the study by Ashcroft, Radford and colleagues, who demonstrated the utility of IM–MS for screening a panel of small molecules for disrupting amyloid formation of human islet amyloid polypeptide (hIAPP) and A β 40 [66^{••},67]. By developing a high throughput screen, several parameters could be assessed simultaneously: protein:ligand interactions; the protein species (monomer, oligomer) to which the drug bound; whether binding was specific or non-specific and the effect of ligand binding on


self-assembly pathways. Ultimately, this led to the identification of novel inhibitors of *in vitro* A β 40 fibril formation.

Furthermore, by combining IM–MS with complementary strategies such as electron-transfer dissociation (ETD) and molecular modelling, additional insight into the mode of ligand binding and the behaviour of specific amino acids in the target protein can be obtained for the observed aggregates [68,69]. Indeed, in combination with NMR and molecular dynamics, IM–MS has recently been used to define the mechanism of binding of the small molecule A β 42 aggregation inhibitor tramiprosate, which is currently in phase III clinical trials for Alzheimer's disease [70].

Intrinsically disordered proteins

Intrinsically disordered proteins (IDPs), which include amyloidogenic proteins such as α -synuclein, lack a well-defined tertiary structure and are believed to adopt a variety of different conformations, including several regions that are predicted to be totally unstructured [71]. IDPs account for a significant percentage of all proteins, with some 40% of human polypeptides

Figure 2



Schematic illustrating IM-MS monitoring of the self-assembly process of different amyloid structures in the absence and presence of an inhibitor. (Top panels) Cartoon mobilograms of amyloid proteins in the absence (left) and presence of an inhibitor of amyloidosis (right). The number of amyloid subunits, n , is determined by MS analysis, while the collision cross section (conformation) of the oligomers is determined using IMS. (Bottom panels) The mechanism proposed by Bleiholder *et al.* [52] suggests that monomers self-assemble leading to the formation of soluble oligomers ($n = 2-4$), at which point there is a transition from a globular conformation to a presumed toxic linear β -sheet structure. In the presence of inhibitors of amyloidosis, aggregates either do not form (not shown) or are thought to maintain an isotropic globular conformation ($n \geq 4$, bottom right).

predicted to contain at least one disordered region. Moreover, ordered:disordered transitions commonly occur during endogenous protein folding subsequent to translation [72]. Defining the structured regions and degree of (dis)order of this important class of proteins is currently restricted, due to the limitations of traditional techniques such as X-ray crystallography, which require a fixed, relatively stable structural protein disposition in order to form crystals. Due to their roles in forming protein complexes implicated in disease, IDPs have become valuable new drug targets. Consequently, understanding changes in structure and conformation that occur upon drug binding can reveal important information about the mode of action of potential therapeutic compounds. The ability of IM-MS to evaluate conformational changes in heterogeneous mixtures with very poorly defined (or absent) higher-order structure thus makes it an ideal technique for IDP interrogation, although its application in this important area is currently underexploited. An important example is the intrinsically disordered transcription factor p53 [73**], a tumour suppressor with a short half-life in cells due to its interaction with the

ubiquitin E3-ligase MDM2, which targets p53 for degradation [74,75]. The dysregulation of p53 in many cancers (and stabilisation upon DNA damage) means that understanding, and potentially disrupting, the p53:MDM2 complex, is a desirable chemotherapeutic strategy that has become an exemplar in the protein:protein interaction field [76]. Using native IM-MS, Dickinson *et al.* evaluated the effect of two small molecules, RITA and Nutelin-3, which were designed to interfere with the formation of the p53:MDM2 complex by binding to either p53 or MDM2 respectively [73**]. The non-covalent RITA/p53 complex was unstable under the relatively benign conditions used in these analyses, suggesting a lower K_D than previously measured in solution, or a requirement for hydrophobic interactions that are lost upon transfer to the gas-phase. However, by evaluating the variance in charge state distribution and CCSD in the absence or presence of RITA, a compound-dependent conformation change in p53 with a modest decrease in protein disorder and compaction, was observed. Similarly, conformational changes were also reported in the N-terminal region of MDM2 in the presence of the high-

affinity ($K_D \sim 100$ nM) small molecule ligand Nutlin-3, which was observed to bind preferentially to a more compact (and relatively inflexible) form of MDM2 [73**]. Based on these important observations relating conformation to binding, it is clear that IM–MS has much to offer in the field of IDPs and protein:protein interactions, and their stabilisation/destabilization by small molecules.

Protein kinases

Protein kinases regulate dynamic protein phosphorylation, which is essential for cell signalling, but are also dysregulated in diseases such as cancer and diabetes. Protein kinases usually cycle between a variety of distinct conformers, presenting numerous opportunities for ligand-binding and conformational trapping. Consequently the human protein kinase superfamily (the kinome) has become a highly valuable class of structurally-distinct targets for therapeutic intervention. Conservation of the protein kinase catalytic domain, in particular the ATP-binding site, means that it is a challenge to selectively modulate specific members of the kinome in this region. Indeed, even after three decades of intensive study, ongoing work still seeks to categorize binding mechanisms of protein kinase inhibitors to help explain conformation-dependent effects in cells. The seminal discovery of kinase inhibitors that induce distinct structural effects on the same target [77] and the synthesis of both allosteric and covalent kinase small molecule inhibitors [78] and activators [79], reinforces the need for technologies to dissect ligand-dependent allosteric communication [80] and conformation-dependent effects of ligands on kinases.

One of the earliest studies using IM–MS to investigate ligand binding to protein kinases studied interaction of the archetypical protein kinase A (PKA) regulatory subunit with analogues of cAMP [81]. Using IM–MS, the antagonistic R-enantiomer of thio-substituted cAMP (RpcAMPS) preferentially bound and stabilised the ‘H-form’ of PKA, while the S-enantiomer agonist SpcAMPS was shown to bind the same conformational state (the ‘B-form’) as the natural ligand cAMP [81]. These studies pave the way for design of novel allosteric PKA R-subunit inhibitors, with a goal of regulating interactions with the PKA catalytic subunit and modulation of the cellular response to G-protein coupled receptors (GPCRs). A separate study employing native MS reports analysis of a pentameric PKA holoenzyme (2 regulatory:2 catalytic subunits) bound to a fragment of the A-kinase anchoring protein AKAP79 under physiological cAMP conditions [82]. It will thus be interesting to evaluate the conformational dynamics (CCSD) of these subunits after selective release from the pentamer, or additionally in the presence of small molecule kinase inhibitors.

In an unrelated study on the same PKA signalling system components, the PKA inhibitor protein (PKI), a very


potent endogenous protein inhibitor of the PKA catalytic subunit (PKAc), was shown by IM–MS to exhibit preferential binding to the more compact catalytically-active form of PKAc associated with C-subunit autophosphorylation (Figure 3) [83**]. Interestingly, CIU studies revealed that the PKI-binding conformer of PKAc exhibited greater structural stability than the PKAc conformer unable to bind to PKI, which was itself much more similar to dephosphorylated PKAc. IM–MS with CIU, and complementary thermal stability studies employing differential scanning fluorimetry (DSF), further demonstrated the effects of PKAc hyper-phosphorylation and conformation-dependent binding of a panel of small molecule kinase inhibitors (including both classical PKA inhibitors such as H89 and the clinical phase I oral multi-AGC kinase inhibitor AT13148). Interestingly, the PKAc:drug complexes exhibited markedly reduced conformational flexibility, confirming that significant structural changes occur upon binding to different classes of small molecule. In an analogous study, IM–MS and enzyme-based strategies were exploited to demonstrate that the atypical two component hexameric histidine kinase ExsG can exist in both a phosphorylated but catalytically inactive ‘compact’ conformation, and an ‘open’ catalytically active conformation that is associated with nucleotide binding [84].

Finally, a key study evaluating drug binding to protein kinases employed a CIU-based IM–MS assay to analyse the model tyrosine protein kinase ABL in the presence of a panel of protein kinase inhibitors [85**]. Compounds were categorized as either ‘type 1’ (ATP-competitive) or allosteric ‘type 2’ inhibitors. Although only 11 protein kinase inhibitors were screened, the scalability of such assays theoretically permits the analysis of hundreds of small molecules per day, using relatively small quantities of enzyme. Furthermore, by undertaking dose-dependent evaluation of ligand binding, K_D values might also be determined with relative ease, circumventing issues associated with analysis of clinically-relevant inactive and pseudokinase conformations found across the kinase superfamily [80,86–90].

Future prospects

Although not yet fully integrated into the arsenal of tools for structural interrogation of protein complexes, several studies have now demonstrated the power of IM–MS and CIU, often in combination with other biophysical techniques, for characterising protein:ligand interactions that are of importance to both basic and pharmaceutical research. Since these procedures can be adapted for low to medium-throughput screening of ligands, they can be readily integrated into drug discovery and target validation pipelines, and will be particularly useful where mechanistic understanding is lacking. However, while IM–MS is a unique ‘conformation-based’ small molecule screening tool that can be used to probe the strength of protein:ligand interactions in the form of K_D value

Figure 3



Conformation-dependent binding of PKI to PKA catalytic domain (PKA_c). Mass spectra (left), ion mobility spectra (middle) and CIU plots (right) of PKA_c in the absence (top) and presence (bottom) of full length PKI protein. PKA_c/PKI in the mass spectrum (bottom left) refers to the non-covalent protein kinase:inhibitor complex. IM-MS of PKA_c demonstrates co-existence of two primary conformations: a more compact conformer able to bind PKI (shaded red), and a more elongated conformer that is unable to bind PKI, termed PKA_c(PKI) (shaded green). CIU plots (right) demonstrate a significant difference in the relative stability of the total PKA_c conformer population compared to the non PKI-binding kinase conformer [PKA_c(PKI)] as demonstrated by the collision voltage required to induce protein unfolding (white dotted line). See Ref. [83**] for further information.

determination, it fails to provide the empirical atomic level detail essential for true target-based drug-design.

In this review, we have focused on clinically relevant protein classes, where better understanding of small molecule binding on protein stability and conformation can reveal insights into therapeutic target development. However, the principles of structural analysis using IM-MS are relevant to protein-ligand binding in any field. It is worth noting that the resolving power of ion mobility separation is still a potential limiting factor, with minor conformational differences (<1%) arising upon small molecule binding especially challenging to define. The commercialisation of a cyclic drift tube in which ions can travel for a variable (increasing) number of cycles before they are ejected, could circumvent this issue [5*,91,92,93*]. Indeed, this type of experimental setup has been demonstrated to increase resolving power up to 20-fold, albeit not yet with proteins, which could in the future permit evaluation of extremely small ligand-driven protein conformational changes.

As with any assay, consideration should also be given to the possibility of non-specific ligand binding, which can be assessed by varying buffer conditions used for 'native' electrospray ionisation (ESI). Excess ligand or the addition of essential buffer components (e.g. salt) can also suppress ESI, resulting in MS spectra of reduced resolution, with poor signal to noise [94,95]. Differential protein ionisation in the absence or presence of ligand, which can sometimes arise due to preferential ionisation of the small molecule, can induce a shift in the ESI charge state envelope, making comparison of the CCS/CCSD for analogous charge states of the bound and unbound protein forms problematic. Dissociation of some weak non-covalent binders that are dependent on hydrophobic interactions may also be lost during transfer to the gas-phase, potentially leading to underestimation of K_D [96]. Here, even more gentle evaporation processes like cold spray ionisation [97], in conjunction with a low temperature drift tube [98,99] could possibly improve confidence in structural elucidation and K_D determination.

IM–MS has enormous potential for the development and screening of ligands, from low molecular weight compounds to therapeutic antibodies, which is only now beginning to be realised. Furthermore, since it is also possible to evaluate binding to differentially modified protein forms (proteoforms) and membrane proteins [19^{*}] that might otherwise be intractable to structural interrogation, IM–MS opens up the possibility of understanding the intricacies of small molecule binding to complex proteoforms, such as differentially phosphorylated or glycosylated protein targets. As well as the small ligands discussed here, IM–MS has demonstrated utility in the evaluation of structural differences in antibodies following drug conjugation, a growth area in the pharmaceutical industry [100]. Structural interrogation of protein:DNA and protein:RNA complexes, to ascertain sequence-specific binding affinity, is also likely to benefit from IM–MS analysis [101,102]. Moreover, with the development of robotic chip based injection systems [103] combined with already available automated open-source software for data extraction, processing and visualisation (e.g. Pulsar [19^{*}], Amphitrite [104], ORIGAMI [44^{*}] and UniDec [105]), the age of high throughput IM–MS-based ligand screening appears to have arrived.

Acknowledgements

The authors acknowledge support from the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/L009501/1, BB/M012557/1, BB/R000182/1 and a BBSRC DTP studentship to SF), North West Cancer Research (CR1037 and CR1088), and the Institute of Integrative Biology, University of Liverpool in the form of a summer internship for KJ.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Lanucara F, Holman SW, Gray CJ, Eyers CE: **The power of ion mobility–mass spectrometry for structural characterization and the study of conformational dynamics.** *Nat Chem* 2014, **6**:281–294.
2. May JC, McLean JA: **Ion mobility–mass spectrometry: time-dispersive instrumentation.** *Anal Chem* 2015, **87**:1422–1436.
3. Wyttenbach T, Kemper PR, Bowers MT: **Design of a new electrospray ion mobility mass spectrometer.** *Int J Mass Spectrom* 2001, **212**:13–23.
4. Bowers MT: **Ion mobility spectrometry: a personal view of its development at UCSB.** *Int J Mass Spectrom* 2014, **370**:75–95.
5. Merenbloom SI, Glaskin RS, Henson ZB, Clemmer DE: **High-resolution ion cyclotron mobility spectrometry.** *Anal Chem* 2009, **81**:1482–1487.
6. Ewing MA, Glover MS, Clemmer DE: **Hybrid ion mobility and mass spectrometry as a separation tool.** *J Chromatogr A* 2016, **1439**:3–25.
7. Kanu AB, Dwivedi P, Tam M, Matz L, Hill HH Jr: **Ion mobility–mass spectrometry.** *J Mass Spectrom* 2008, **43**:1–22.
8. Renaud JP, Chung CW, Danielson UH, Egner U, Hennig M, Hubbard RE, Nar H: **Biophysics in drug discovery: impact, challenges and opportunities.** *Nat Rev Drug Discov* 2016, **15**:679–698.
9. van Duijn E, Barendregt A, Synowsky S, Versluis C, Heck AJ: **Chaperonin complexes monitored by ion mobility mass spectrometry.** *J Am Chem Soc* 2009, **131**:1452–1459.
10. Uetrecht C, Rose RJ, van Duijn E, Lorenzen K, Heck AJ: **Ion mobility mass spectrometry of proteins and protein assemblies.** *Chem Soc Rev* 2010, **39**:1633–1655.
11. Ruotolo BT, Benesch JL, Sandercock AM, Hyung SJ, Robinson CV: **Ion mobility–mass spectrometry analysis of large protein complexes.** *Nat Protoc* 2008, **3**:1139–1152.
12. Cubrilovic D, Barylyuk K, Hofmann D, Walczak MJ, Graeber M, Berg T, Widerb G, Zenobi R: **Direct monitoring of protein–protein inhibition using nano electrospray ionization mass spectrometry.** *Chem Sci* 2014, **5**:2794–2803.
13. Atmanene C, Petiot-Becard S, Zeyer D, Van Dorsselaer A, Vivat Hannah V, Sanglier-Cianferani S: **Exploring key parameters to detect subtle ligand-induced protein conformational changes using traveling wave ion mobility mass spectrometry.** *Anal Chem* 2012, **84**:4703–4710.
14. Stojko J, Fieulaine S, Petiot-Becard S, Van Dorsselaer A, Meinzel T, Giglione C, Cianferani S: **Ion mobility coupled to native mass spectrometry as a relevant tool to investigate extremely small ligand-induced conformational changes.** *Analyst* 2015, **140**:7234–7245.
15. El-Hawiet A, Kitova EN, Arutyunov D, Simpson DJ, Szymanski CM, Klassen JS: **Quantifying ligand binding to large protein complexes using electrospray ionization mass spectrometry.** *Anal Chem* 2012, **84**:3867–3870.
16. Lin H, Kitova EN, Klassen JS: **Quantifying protein–ligand interactions by direct electrospray ionization–MS analysis: evidence of nonuniform response factors induced by high molecular weight molecules and complexes.** *Anal Chem* 2013, **85**:8919–8922.
17. Niu S, Rabuck JN, Ruotolo BT: **Ion mobility–mass spectrometry of intact protein–ligand complexes for pharmaceutical drug discovery and development.** *Curr Opin Chem Biol* 2013, **17**:809–817.
18. Mehmood S, Allison TM, Robinson CV: **Mass spectrometry of protein complexes: from origins to applications.** *Annu Rev Phys Chem* 2015, **66**:453–474.
19. Allison TM, Reading E, Liko I, Baldwin AJ, Laganowsky A, Robinson CV: **Quantifying the stabilizing effects of protein–ligand interactions in the gas phase.** *Nat Commun* 2015, **6**:8551.
20. Ahdash Z, Pyle E, Politis A: **Hybrid mass spectrometry: towards characterization of protein conformational states.** *Trends Biochem Sci* 2016, **41**:650–653.
21. Le Gall T, Romero PR, Cortese MS, Uversky VN, Dunker AK: **Intrinsic disorder in the protein data bank.** *J Biomol Struct Dyn* 2007, **24**:325–342.
22. Politis A, Park AY, Hyung SJ, Barsky D, Ruotolo BT, Robinson CV: **Integrating ion mobility mass spectrometry with molecular modelling to determine the architecture of multiprotein complexes.** *PLoS One* 2010, **5**:e12080.
23. Politis A, Stengel F, Hall Z, Hernandez H, Leitner A, Walzthoeni T, Robinson CV, Aebersold R: **A mass spectrometry-based hybrid method for structural modeling of protein complexes.** *Nat Methods* 2014, **11**:403–406.
24. D’Urzo A, Konijnenberg A, Rossetti G, Habchi J, Li J, Carloni P, Sobott F, Longhi S, Grandori R: **Molecular basis for structural heterogeneity of an intrinsically disordered protein bound to a partner by combined ESI–IM–MS and modeling.** *J Am Soc Mass Spectrom* 2015, **26**:472–481.

25. Politis A, Park AY, Hall Z, Ruotolo BT, Robinson CV: **Integrative modelling coupled with ion mobility mass spectrometry reveals structural features of the clamp loader in complex with single-stranded DNA binding protein.** *J Mol Biol* 2013, **425**:4790-4801.
26. Leney AC, Heck AJ: **Native mass spectrometry: what is in the name?** *J Am Soc Mass Spectrom* 2017, **28**:5-13.
27. Jurneczko E, Barran PE: **How useful is ion mobility mass spectrometry for structural biology? The relationship between protein crystal structures and their collision cross sections in the gas phase.** *Analyst* 2011, **136**:20-28.
28. Mason EA, McDaniel EW: *Transport Properties of Ion Gases*. Wiley; 1988.
29. Cumeras R, Figueras E, Davis CE, Baumbach JI, Gracia I: **Review on ion mobility spectrometry. Part 1: current instrumentation.** *Analyst* 2015, **140**:1376-1390.
30. Mason EA, Schamp HW Jr: **Mobility of gaseous ions in weak electric fields.** *Ann Phys* 1958, **4**:233-270.
31. Michelmann K, Silveira JA, Ridgeway ME, Park MA: **Fundamentals of trapped ion mobility spectrometry.** *J Am Soc Mass Spectrom* 2015, **26**:14-24.
32. Giles K, Pringle SD, Worthington KR, Little D, Wildgoose JL, Bateman RH: **Applications of a travelling wave-based radio-frequency-only stacked ring ion guide.** *Rapid Commun Mass Spectrom* 2004, **18**:2401-2414.
33. Chawner R, McCullough B, Giles K, Barran PE, Gaskell SJ, Eyers CE: **QconCAT standard for calibration of ion mobility-mass spectrometry systems.** *J Proteome Res* 2012, **11**:5564-5572.
34. Sun Y, Vahidi S, Sowole MA, Konermann L: **Protein structural studies by traveling wave ion mobility spectrometry: a critical look at electrospray sources and calibration issues.** *J Am Soc Mass Spectrom* 2016, **27**:31-40.
35. Allison TM, Landreh M, Benesch JLP, Robinson CV: **Low charge and reduced mobility of membrane protein complexes has implications for calibration of collision cross section measurements.** *Anal Chem* 2016, **88**:5879-5884.
36. Bush MF, Hall Z, Giles K, Hoyes J, Robinson CV, Ruotolo BT: **Collision cross sections of proteins and their complexes: a calibration framework and database for gas-phase structural biology.** *Anal Chem* 2010, **82**:9557-9565.
37. Guevremont R: **High-field asymmetric waveform ion mobility spectrometry: a new tool for mass spectrometry.** *J Chromatogr A* 2004, **1058**:3-19.
38. Swearingen KE, Moritz RL: **High-field asymmetric waveform ion mobility spectrometry for mass spectrometry-based proteomics.** *Exp Rev Proteomics* 2012, **9**:505-517.
39. Daniel JM, McCombie G, Wendt S, Zenobi R: **Mass spectrometric determination of association constants of adenylate kinase with two noncovalent inhibitors.** *J Am Soc Mass Spectrom* 2003, **14**:442-448.
40. Hopper JT, Oldham NJ: **Collision induced unfolding of protein ions in the gas phase studied by ion mobility-mass spectrometry: the effect of ligand binding on conformational stability.** *J Am Soc Mass Spectrom* 2009, **20**:1851-1858.
- One of the earliest studies applying elevated collision energy to understand the effects of ligand binding on protein unfolding pathways, confirming that gas-phase CIU studies are similar to solution-phase observations.
41. Freeke J, Bush MF, Robinson CV, Ruotolo BT: **Gas-phase protein assemblies: unfolding landscapes and preserving native-like structures using noncovalent adducts.** *Chem Phys Lett* 2012, **524**:1-9.
42. Bornschein RE, Niu S, Eschweiler J, Ruotolo BT: **Ion mobility-mass spectrometry reveals highly-compact intermediates in the collision induced dissociation of charge-reduced protein complexes.** *J Am Soc Mass Spectrom* 2016, **27**:41-49.
43. Eschweiler JD, Rabuck-Gibbons JN, Tian YW, Ruotolo BT: **CIUSuite: a quantitative analysis package for collision induced unfolding measurements of gas-phase protein ions.** *Anal Chem* 2015, **87**:11516-11522.
44. Migas LG, France AP, Bellina B, Barran PE: **ORIGAMI: a software suite for activated ion mobility mass spectrometry (aIM-MS) applied to multimeric protein assemblies.** *Int J Mass Spectrom* 2017. in press.
- Describes a software suite that facilitates the rapid acquisition, analysis and visualisation of CIU IM-MS data on a Waters Synapt instrument.
45. Kirkitadze MD, Bitan G, Teplow DB: **Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies.** *J Neurosci Res* 2002, **69**:567-577.
46. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr: **Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.** *Proc Natl Acad Sci U S A* 2000, **97**:571-576.
47. Meier JJ, Kayed R, Lin CY, Gurlo T, Haataja L, Jayasinghe S, Langen R, Glabe CG, Butler PC: **Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP.** *Am J Physiol Endocrinol Metab* 2006, **291**:E1317-E1324.
48. Eisenberg DS, Sawaya MR: **Structural studies of amyloid proteins at the molecular level.** *Annu Rev Biochem* 2017, **86**:69-95.
49. Hoffmann W, von Helden G, Pagel K: **Ion mobility-mass spectrometry and orthogonal gas-phase techniques to study amyloid formation and inhibition.** *Curr Opin Struct Biol* 2017, **46**:7-15.
- This review highlights advances in the characterisation of amyloid aggregation and their assembly pathways using IM-MS and how this technology can be used to screen for molecules that disrupt oligomer formation.
50. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P, Nomenclature Committee of the International Society of A: **Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis.** *Amyloid* 2012, **19**:167-170.
51. Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, Bitan G, Teplow DB, Shea JE, Ruotolo BT, Robinson CV, Bowers MT: **Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease.** *Nat Chem* 2009, **1**:326-331.
- Using IM-MS, the authors were able to study the self-assembly mechanisms of different amyloids and suggest a possible candidate oligomer, the Aβ42 dodecamer, as the causative agent responsible for Alzheimer's disease.
52. Bleiholder C, Dupuis NF, Wyttenbach T, Bowers MT: **Ion mobility-mass spectrometry reveals a conformational conversion from random assembly to beta-sheet in amyloid fibril formation.** *Nat Chem* 2011, **3**:172-177.
53. Susa AC, Wu C, Bernstein SL, Dupuis NF, Wang H, Raleigh DP, Shea JE, Bowers MT: **Defining the molecular basis of amyloid inhibitors: human islet amyloid polypeptide-insulin interactions.** *J Am Chem Soc* 2014, **136**:12912-12919.
54. Liu YQ, Graetz M, Ho L, Pukala TL: **Ion mobility-mass spectrometry-based screening for inhibition of alpha-synuclein aggregation.** *Eur J Mass Spectrom* 2015, **21**:255-264.
55. Woods LA, Radford SE, Ashcroft AE: **Advances in ion mobility spectrometry-mass spectrometry reveal key insights into amyloid assembly.** *Biochim Biophys Acta* 2013, **1834**:1257-1268.
56. Seo J, Hoffmann W, Warnke S, Huang X, Gewinner S, Schollkopf W, Bowers MT, von Helden G, Pagel K: **An infrared spectroscopy approach to follow beta-sheet formation in peptide amyloid assemblies.** *Nat Chem* 2017, **9**:39-44.
57. Bernstein SL, Wyttenbach T, Baumketner A, Shea JE, Bitan G, Teplow DB, Bowers MT: **Amyloid beta-protein: monomer structure and early aggregation states of Abeta42 and its Pro19 alloform.** *J Am Chem Soc* 2005, **127**:2075-2084.

58. Amijee H, Bate C, Williams A, Virdee J, Jeggo R, Spanswick D, Scopes DI, Treherne JM, Mazzitelli S, Chawner R, Eyers CE, Doig AJ: **The N-methylated peptide SEN304 powerfully inhibits Abeta(1–42) toxicity by perturbing oligomer formation.** *Biochemistry* 2012, **51**:8338–8352.
59. Gessel MM, Wu C, Li H, Bitan G, Shea JE, Bowers MT: **Abeta(39–42) modulates Abeta oligomerization but not fibril formation.** *Biochemistry* 2012, **51**:108–117.
60. Zheng X, Liu D, Klarner FG, Schrader T, Bitan G, Bowers MT: **Amyloid beta–protein assembly: the effect of molecular tweezers CLR01 and CLR03.** *J Phys Chem B* 2015, **119**:4831–4841.
61. Soper MT, DeToma AS, Hyung SJ, Lim MH, Ruotolo BT: **Amyloid-beta–neuropeptide interactions assessed by ion mobility–mass spectrometry.** *Phys Chem Chem Phys* 2013, **15**:8952–8961.
62. Murray MM, Bernstein SL, Nyugen V, Condron MM, Teplow DB, Bowers MT: **Amyloid beta protein: Abeta40 inhibits Abeta42 oligomerization.** *J Am Chem Soc* 2009, **131**:6316–6317.
63. Young LM, Cao P, Raleigh DP, Ashcroft AE, Radford SE: **Ion mobility spectrometry–mass spectrometry defines the oligomeric intermediates in amylin amyloid formation and the mode of action of inhibitors.** *J Am Chem Soc* 2014, **136**:660–670.
- Provides novel insights into the formation of amylin oligomers which are found in the pancreatic islets of people with type II diabetes and identifies the specific conformers to which two known inhibitors bind. In addition, the authors use IMS–MS to reveal the distinct modes of action of the inhibitors in preventing oligomer formation.
64. Zheng X, Wu C, Liu D, Li H, Bitan G, Shea JE, Bowers MT: **Mechanism of C-terminal fragments of amyloid beta-protein as Abeta inhibitors: do C-terminal interactions play a key role in their inhibitory activity?** *J Phys Chem B* 2016, **120**:1615–1623.
65. de Almeida NE, Do TD, Tro M, LaPointe NE, Feinstein SC, Shea JE, Bowers MT: **Opposing effects of Cucurbit[7]uril and 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose on amyloid beta25–35 assembly.** *ACS Chem Neurosci* 2016, **7**:218–226.
66. Young LM, Saunders JC, Mahood RA, Revill CH, Foster RJ, Tu LH, Raleigh DP, Radford SE, Ashcroft AE: **Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry–mass spectrometry.** *Nat Chem* 2015, **7**:73–81.
- This study exemplifies the ability of IM–MS to be used as a tool to rapidly determine the conformation effects and mode of binding of small molecules to amyloids, and describes a potential lead compound for disrupting pathogenic Aβ40 fibril formation.
67. Young LM, Saunders JC, Mahood RA, Revill CH, Foster RJ, Ashcroft AE, Radford SE: **ESI-IMS-MS: a method for rapid analysis of protein aggregation and its inhibition by small molecules.** *Methods* 2016, **95**:62–69.
68. Cole H, Porrini M, Morris R, Smith T, Kalapothakis J, Weidt S, Mackay CL, MacPhee CE, Barran PE: **Early stages of insulin fibrillogenesis examined with ion mobility mass spectrometry and molecular modelling.** *Analyst* 2015, **140**:7000–7011.
69. Konijnenberg A, Ranica S, Narkiewicz J, Legname G, Grandori R, Sobott F, Natalello A: **Opposite structural effects of epigallocatechin-3-gallate and dopamine binding to alpha-synuclein.** *Anal Chem* 2016, **88**:8468–8475.
70. Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, Fillit H, Hey JA: **Elucidating the Abeta42 anti-aggregation mechanism of action of tramiprosate in Alzheimer's disease: integrating molecular analytical methods.** *Pharmacokin Clin Data CNS Drugs* 2017, **31**:495–509.
71. Dunker AK, Lawson JD, Brown CJ, Williams RM, Romero P, Oh JS, Oldfield CJ, Campen AM, Ratliff CM, Hipps KW *et al.*: **Intrinsically disordered protein.** *J Mol Graph Model* 2001, **19**:26–59.
72. Uversky VN, Dunker AK: **Understanding protein non-folding.** *Biochim Biophys Acta* 2010, **1804**:1231–1264.
73. Dickinson ER, Jurneczko E, Nicholson J, Hupp TR, Zawacka-Pankau J, Selivanova G, Barran PE: **The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors.** *Front Mol Biosci* 2015, **2**:39.
- Highlights how IM–MS can be used to investigate ligand binding to intrinsically disordered proteins. Demonstrates conformer specific small molecule binding and stabilisation of protein structure.
74. Lane DP: **Cancer. p53, guardian of the genome.** *Nature* 1992, **358**:15–16.
75. Wu X, Bayle JH, Olson D, Levine AJ: **The p53–mdm-2 autoregulatory feedback loop.** *Genes Dev* 1993, **7**:1126–1132.
76. Wang S, Zhao Y, Aguilar A, Bernard D, Yang CY: **Targeting the MDM2–p53 protein–protein interaction for new cancer therapy: progress and challenges.** *Cold Spring Harb Perspect Med* 2017:7.
77. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J: **Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).** *Cancer Res* 2002, **62**:4236–4243.
78. Byrne DP, Foulkes DM, Eyers PA: **Pseudokinases: update on their functions and evaluation as new drug targets.** *Future Med Chem* 2017, **9**:245–265.
79. Leroux AE, Schulze JO, Biondi RM: **AGC kinases, mechanisms of regulation and innovative drug development.** *Semin Cancer Biol* 2017, **17** 30148–7.
80. Mohanty S, Oruganty K, Kwon A, Byrne DP, Ferries S, Ruan Z, Hanold LE, Katiyar S, Kennedy EJ, Eyers PA, Kannan N: **Hydrophobic core variations provide a structural framework for tyrosine kinase evolution and functional specialization.** *PLoS Genet* 2016, **12**:e1005885.
81. Badireddy S, Yunfeng G, Ritchie M, Akamine P, Wu J, Kim CW, Taylor SS, Qingsong L, Swaminathan K, Anand GS: **Cyclic AMP analog blocks kinase activation by stabilizing inactive conformation: conformational selection highlights a new concept in allosteric inhibitor design.** *Mol Cell Proteomics* 2011, **10** M110 004390.
82. Smith FD, Esseltine JL, Nygren PJ, Veessler D, Byrne DP, Vonderach M, Strashnov I, Eyers CE, Eyers PA, Langeberg LK, Scott JD: **Local protein kinase A action proceeds through intact holoenzymes.** *Science* 2017, **356**:1288–1293.
83. Byrne DP, Vonderach M, Ferries S, Brownridge PJ, Eyers CE, Eyers PA: **cAMP-dependent protein kinase (PKA) complexes probed by complementary differential scanning fluorimetry and ion mobility–mass spectrometry.** *Biochem J* 2016, **473**:3159–3175.
- By using IM–MS the authors were able to demonstrate dynamic, conformationally distinct populations of the PKA catalytic subunit with distinct structural stability and susceptibility to both the inhibitor protein PKI and small molecule drugs.
84. Wojnowska M, Yan J, Sivalingam GN, Cryar A, Gor J, Thalassinou K, Djordjevic S: **Autophosphorylation activity of a soluble hexameric histidine kinase correlates with the shift in protein conformational equilibrium.** *Chem Biol* 2013, **20**:1411–1420.
85. Rabuck JN, Hyung SJ, Ko KS, Fox CC, Soellner MB, Ruotolo BT: **Activation state-selective kinase inhibitor assay based on ion mobility–mass spectrometry.** *Anal Chem* 2013, **85**:6995–7002.
- This study demonstrates the power of IM–MS for screening small molecule kinase inhibitors and defining the mode of binding as either direct or allosteric, independent of catalytic activity.
86. Murphy JM, Mace PD, Eyers PA: **Live and let die: insights into pseudoenzyme mechanisms from structure.** *Curr Opin Struct Biol* 2017, **47**:95–104.
87. Milani M, Byrne DP, Greaves G, Butterworth M, Cohen GM, Eyers PA, Varadarajan S: **DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis.** *Cell Death Dis* 2017, **8**:e2552.
88. Bailey FP, Byrne DP, Oruganty K, Eyers CE, Novotny CJ, Shokat KM, Kannan N, Eyers PA: **The Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent manner.** *Biochem J* 2015, **467**:47–62.

89. Bailey FP, Byrne DP, McSkimming D, Kannan N, Evers PA: **Going for broke: targeting the human cancer pseudokinome.** *Biochem J* 2015, **465**:195-211.
90. Murphy JM, Zhang Q, Young SN, Reese ML, Bailey FP, Evers PA, Ungureanu D, Hammaren H, Silvennoinen O, Varghese LN *et al.*: **A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties.** *Biochem J* 2014, **457**:323-334.
91. Glaskin RS, Valentine SJ, Clemmer DE: **A scanning frequency mode for ion cyclotron mobility spectrometry.** *Anal Chem* 2010, **82**:8266-8271.
92. Glaskin RS, Ewing MA, Clemmer DE: **Ion trapping for ion mobility spectrometry measurements in a cyclical drift tube.** *Anal Chem* 2013, **85**:7003-7008.
93. Haler JRN, Far J, Aqil A, Claereboudt J, Tomczyk N, Giles K, Jerome C, De Pauw E: **Multiple gas-phase conformations of a synthetic linear poly(acrylamide) polymer observed using ion mobility-mass spectrometry.** *J Am Soc Mass Spectrom* 2017, **28**:2492-2499.
- Demonstration of a prototype commercial high resolution multi-pass cyclic travelling-wave ion mobility MS instrument.
94. Wang W, Kitova EN, Klassen JS: **Nonspecific protein-carbohydrate complexes produced by nanoelectrospray ionization. Factors influencing their formation and stability.** *Anal Chem* 2005, **77**:3060-3071.
95. Guan S, Trnka MJ, Bushnell DA, Robinson PJ, Gestwicki JE, Burlingame AL: **Deconvolution method for specific and nonspecific binding of ligand to multiprotein complex by native mass spectrometry.** *Anal Chem* 2015, **87**:8541-8546.
96. Bich C, Baer S, Jecklin MC, Zenobi R: **Probing the hydrophobic effect of noncovalent complexes by mass spectrometry.** *J Am Soc Mass Spectrom* 2010, **21**:286-289.
97. Yamaguchi K: **Cold-spray ionization mass spectrometry: principle and applications.** *J Mass Spectrom* 2003, **38**:473-490.
98. May JC, Russell DH: **A mass-selective variable-temperature drift tube ion mobility-mass spectrometer for temperature dependent ion mobility studies.** *J Am Soc Mass Spectrom* 2011, **22**:1134-1145.
99. Ujma J, Giles K, Morris M, Barran PE: **New high resolution ion mobility mass spectrometer capable of measurements of collision cross sections from 150 to 520 K.** *Anal Chem* 2016, **88**:9469-9478.
100. Debaene F, Boeuf A, Wagner-Rousset E, Colas O, Ayoub D, Corvaia N, Van Dorsselaer A, Beck A, Cianferani S: **Innovative native MS methodologies for antibody drug conjugate characterization: high resolution native MS and IM-MS for average DAR and DAR distribution assessment.** *Anal Chem* 2014, **86**:10674-10683.
101. Atmanene C, Chaix D, Bessin Y, Declerck N, Van Dorsselaer A, Sanglier-Cianferani S: **Combination of noncovalent mass spectrometry and traveling wave ion mobility spectrometry reveals sugar-induced conformational changes of central glycolytic genes repressor/DNA complex.** *Anal Chem* 2010, **82**:3597-3605.
102. Ma X, Shah S, Zhou M, Park CK, Wysocki VH, Horton NC: **Structural analysis of activated SgrAI-DNA oligomers using ion mobility mass spectrometry.** *Biochemistry* 2013, **52**:4373-4381.
103. Dethy JM, Ackermann BL, Delatour C, Henion JD, Schultz GA: **Demonstration of direct bioanalysis of drugs in plasma using nanoelectrospray infusion from a silicon chip coupled with tandem mass spectrometry.** *Anal Chem* 2003, **75**:805-811.
104. Sivalingam GN, Yan J, Sahota H, Thalassinou K: **Amphitrite: a program for processing travelling wave ion mobility mass spectrometry data.** *Int J Mass Spectrom* 2013, **345**:54-62.
105. Marty MT, Baldwin AJ, Marklund EG, Hochberg GK, Benesch JL, Robinson CV: **Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles.** *Anal Chem* 2015, **87**:4370-4376.